Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737 · View on ClinicalTrials.gov ↗
Study Summary
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.
Conditions Studied
Interventions
- DRUG HH2853 Tablets
Study Locations (20)
Beijing Municipality
- Beijing Cancer Hospital — Beijing
- Beijing Cancer Hospital — Beijing
- Beijing Jishuitan Hospital — Beijing
Liaoning
- Liaoning Cancer Hospital&Institute — Shenyang
- Shengjing Hospital Of China Medical University — Shenyang
Shanghai Municipality
- Shanghai Sixth People's Hospital — Shanghai
- Zhongshan Hospital Fudan University — Shanghai
Arizona
- Mayo Clinic — Phoenix
Florida
- Mayo Clinic — Jacksonville
Minnesota
- Mayo Clinic — Rochester
Texas
- NEXT Oncology — San Antonio
Anhui
- The First Affiliated Hospital of Anhui Medical University — Hefei
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2020-09-08 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04390737
The ClinicalTrials.gov registry entry for NCT04390737 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Haihe Biopharma Co., which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention — of which HH2853 Tablets is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04390737 reports 20 study locations spanning 16 distinct geographic areas — top geographies include Beijing Municipality, Liaoning, Shanghai Municipality. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04390737 about?
NCT04390737 is a clinical study titled "Evaluate the Safety and Clinical Activity of HH2853". This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.
What is the current status of trial NCT04390737?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 254 participants. The study started on 2020-09-08. Estimated completion is 2028-12-31.
What conditions does trial NCT04390737 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Peripheral T Cell Lymphoma, Epithelioid Sarcoma, FL Lymphoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04390737?
The interventions under investigation include: HH2853 Tablets (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04390737?
This trial is sponsored by Haihe Biopharma Co., which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04390737 being conducted?
This trial has 20 study locations across Arizona, Florida, Minnesota, Texas, Anhui. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.